文献速递银屑病与炎症性皮肤病

司库奇尤单抗对斑块状银屑病患者代谢及肝脏指标的影响

Effects of secukinumab on metabolic and liver parameters in plaque psoriasis patients.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2019-10-10

本文为三项III期随机对照试验(FIXTURE、ERASURE、SCULPTURE,n=3010)的事后汇总探索性分析,评估司库奇尤单抗150mg或300mg、安慰剂或依那西普50mg治疗52周内代谢及肝脏指标的变化。结果显示司库奇尤单抗降低hs-CRP,体重和尿酸呈下降趋势,对空腹血糖、血脂和肝酶呈中性影响。

要点

  • 司库奇尤单抗治疗52周可降低hs-CRP水平,体重与尿酸呈下降趋势。
  • 对空腹血糖、血脂参数及肝酶呈中性影响。
  • 肥胖可减弱治疗期间hs-CRP的下降幅度。

核心结论

  • 司库奇尤单抗治疗下代谢与肝脏指标呈中性至有利的长期趋势。
  • 代谢共病与基线hs-CRP升高相关,反映系统性炎症在其病理生理中的作用。

研究设计与样本

  • 三项III期随机对照试验(FIXTURE、ERASURE、SCULPTURE)的汇总事后探索性分析,共n=3010。
  • 患者接受司库奇尤单抗150mg或300mg、安慰剂或依那西普50mg(仅FIXTURE)治疗,纵向评估52周。

主要发现

  • 司库奇尤单抗治疗降低hs-CRP水平。
  • 体重和尿酸水平在司库奇尤单抗治疗52周内呈下降趋势。
  • 银屑病关节炎、代谢综合征、肥胖、糖代谢受损和高尿酸血症各自与基线hs-CRP水平升高相关。
  • 合并肥胖减弱了治疗期间hs-CRP的下降。

临床怎么用

  • 对于合并代谢及肝脏共病的斑块状银屑病患者,司库奇尤单抗在52周内对代谢和肝脏指标呈中性至有利趋势。
  • 合并肥胖患者治疗期间hs-CRP下降可能减弱,需关注其系统性炎症状态。

局限性

  • 本文为事后探索性分析,非预设主要终点。
  • 依那西普对照仅来自FIXTURE研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Psoriasis is associated with metabolic, liver and cardiovascular comorbidity. Secukinumab, a fully human monoclonal antibody that selectively neutralizes interleukin-17A, has shown significant and sustained efficacy in the treatment of moderate to severe psoriasis. OBJECTIVES: This was an exploratory post hoc analysis of pooled data from three phase 3 studies in plaque psoriasis patient populations. The objective was to show the course of metabolic and liver parameters under secukinumab, etanercept or placebo treatment over time. A further objective was to assess the impact of selected comorbidities and metabolic characteristics on high-sensitivity C-reactive protein (hs-CRP), as a surrogate marker of systemic inflammation. METHODS: Data from the phase 3 randomized controlled trials [FIXTURE (NCT01358578), ERASURE (NCT01365455) and SCULPTURE (NCT01406938); n = 3010] were included in this analysis. Patients were treated with secukinumab 150 mg or 300 mg, placebo or etanercept 50 mg (FIXTURE only) as active comparator. A set of metabolic and liver parameters was longitudinally assessed over 52 weeks. Multivariate regression analyses assessed the impact of selected comorbidities and metabolic characteristics on hs-CRP levels at baseline and under treatment. RESULTS: Secukinumab treatment reduced hs-CRP levels. Body weight and uric acid levels tended to decrease over 52 weeks with secukinumab. Secukinumab showed a neutral effect on fasting plasma glucose, lipid parameters and liver enzymes. Psoriatic arthritis, metabolic syndrome, obesity, impaired glucose metabolism, and hyperuricemia were each associated with increased hs-CRP levels at baseline. Concomitant obesity attenuated the decline in hs-CRP under treatment. CONCLUSIONS: These analyses suggest neutral to favourable long-term trends in metabolic and liver parameters under secukinumab treatment. Metabolic comorbidities were associated with increased hs-CRP levels, reflecting the role of systemic inflammatory processes in their pathophysiology.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Gerdes S, Pinter A, Papavassilis C, et al. Effects of secukinumab on metabolic and liver parameters in plaque psoriasis patients. J Eur Acad Dermatol Venereol. 2019. PMID: 31599476. doi:10.1111/jdv.16004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。